Thyroid and parathyroid disorders

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 02/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1106 times

43 Thyroid and parathyroid disorders

Thyroid physiology

The thyroid gland consists of two lobes and is situated in the lower neck. The gland synthesises, stores and releases two major metabolically active hormones: Tetra-iodothyronine (Thyroxine, T4) and tri-iodothyronine (T3). Regulation of hormone synthesis is by variable secretion of the glycoprotein hormone TSH from the anterior pituitary. In turn, TSH is regulated by hypothalamic secretion of the tripeptide thyrotrophin-releasing hormone (TRH) (Fig. 43.1). Low circulating levels of thyroid hormones initiate the release of TSH and probably also TRH. Rising levels of TSH promote increased iodide trapping by the gland and a subsequent increase in thyroid hormone synthesis. The increase in circulating hormone levels feeds back on the pituitary and hypothalamus, shutting off TRH, TSH and further hormone synthesis.

Both T4 and T3 are produced within the follicular cells in the thyroid. The stages in synthesis are shown in Fig. 43.2. In summary:

The ratio of T4:T3 secreted by the thyroid gland is approximately 10:1. Consequently, the gland secretes approximately 80–100 μcg of T4 and 10 μcg of T3 per day. However, only 10% of circulating T3 is derived from direct thyroidal secretion, the remaining 90% being produced by peripheral conversion from T4. T4 can therefore be considered a prohormone that is converted in the peripheral tissues (liver, kidney and brain) either to the active hormone T3 or to the biologically inactive reverse T3 (rT3). In the circulation, the hormones exist in both the active free and inactive protein-bound forms. T4 is 99.98% bound, with only 0.02% circulating free. T3 is slightly less protein bound (99.8%), resulting in a considerably higher circulating free fraction (0.2%). Details of protein binding are shown in Table 43.1.

Table 43.1 Plasma protein binding of thyroid hormones

Carrier protein Plasma concentration Proportion of T4 and T3 bound (%)
Thyroid-binding globulin (TBG) 15 mg/L 75
Transthyretin (formerly thyroid-binding prealbumin) 250 mg/L 10
Albumin 40 g/L 15

The hormones are metabolised in the periphery (kidney, liver and heart) by deiodination. T4 and T3 are also eliminated by biliary secretion of their glucuronide and sulphate conjugates (15–20%). The half-life of T4 in plasma is about 6–7 days and that of T3 24–36 h in euthyroid adults. The apparent volume of distribution for T4 is about 10 L and for T3 about 40 L.

Hypothyroidism

Hypothyroidism is the clinical state resulting from decreased production of thyroid hormones or very rarely from tissue resistance.

Aetiology

Primary hypothyroidism accounts for more than 95% of adult cases. It is usually due to a failure of the thyroid gland itself as a result of autoimmune destruction, or the effects of treatment of thyrotoxicosis. Hypothyroidism may be drug induced. Amiodarone and lithium cause hypothyroidism in around 10% of patients treated (see later). Secondary disease is due to hypopituitarism, and tertiary disease due to failure of the hypothalamus. Peripheral hypothyroidism is due to tissue insensitivity to the action of thyroid hormones. A more extensive classification is shown in Box 43.1.

Iodides may produce hypothyroidism in patients who are particularly sensitive to their ability to block the active transport pump of the thyroid gland. Iodine absorption from topical iodine-containing antiseptics has been shown to cause hypothyroidism in neonates. This is potentially very dangerous at a critical time of neurological development in the newborn infant. Transient hypothyroidism may be seen in 25% of iodine-exposed infants.

Clinical manifestations

Hypothyroidism can affect multiple body systems, but symptoms are mainly non specific and gradual in onset (Box 43.2). Symptoms are frequently vague especially in the early stages. It is common for symptoms to be incorrectly attributed by patients and their relatives to increasing age. The reverse is also common in that patients who have read about, or have friends/family with, hypothyroidism will assume that it is responsible for symptoms of fatigue and weight gain. Thus, hypothyroidism is often confused with simple obesity and depression. Thyroid function tests give accurate diagnosis in all cases.

Box 43.2 Signs and symptoms of hypothyroidism

Skin and appendages Dry, cool, flaking, thickened skin
Reduced sweating
Yellowish complexion. Puffy facies and eyes
Sparse, coarse, dry hair
Brittle nails
Neuromuscular system Slow speech
Poor memory and reduced cognitive function
Somnolence
Carpal tunnel syndrome
Psychiatric disturbance
Hearing loss
Depression
Muscle pain and weakness
Delayed deep tendon reflexes
Metabolic abnormalities Raised total and LDL cholesterol
Macrocytic anaemia
Gastro-intestinal Weight gain with decreased appetite
Abdominal distension and ascites
Constipation
Cardiovascular Reduced cardiac output
Bradycardia
Cardiac enlargement

The most useful clinical signs are myotonic (slow-relaxing) tendon reflexes, bradycardia, hair loss and cool, dry skin. Effusions may occur into pericardial, pleural, peritoneal or joint spaces. Mild anaemia of a macrocytic type is quite common and responds to thyroxine replacement. Pernicious anaemia is a frequent concomitant finding in hypothyroidism. Other, organ-specific autoimmune diseases such as Addison’s disease may be associated.

Investigations

The laboratory investigation of hypothyroidism is extremely simple. Usually clinical assessment, combined with a single estimation of thyroid hormones and TSH, is sufficient to make the diagnosis. In primary disease, the levels of free T4 and T3 are low and the TSH level rises markedly. Some laboratories offer only TSH as a first-line test of thyroid function though this can result in delayed diagnosis of secondary or tertiary hypothyroidism, which should be suspected on the basis of a low free T4 along with low TSH levels.

Elevation of the TSH level occurs early in the course of thyroid failure and may be present before overt clinical manifestations appear. It is important to appreciate that hypothyroidism is not one disease but a spectrum. Early hypothyroidism may be asymptomatic or the symptoms less obvious and non-specific, but a normal TSH with normal free T4 effectively excludes the diagnosis.

A chest radiograph may detect the presence of effusions, and an electrocardiogram (ECG) is useful, especially in patients with angina or coronary heart disease, in whom replacement therapy needs to be introduced gradually.

Testing thyroid function

As indicated earlier (and later in the section on thyrotoxicosis), a clinical assessment and measurement of free T4 and TSH are usually all that are necessary to arrive at an accurate diagnosis of thyroid state. All modern TSH assays now employ double antibody immunometric techniques, which are robust and highly reliable. Moreover, these assays are now so sensitive that they are able to identify thyrotoxic patients with TSH levels below the normal euthyroid range. Commercial free T4 and free T3 assays, however, are all indirect methods and are subject to interference from drugs and other disease states. As such, both T3 and T4 can be decreased as a non-specific consequence of systemic illness (‘sick euthyroid’ syndrome) and depression along with a host of drugs (Surks and Sievert, 1995), which can interfere with thyroid hormone metabolism and free hormone assays (Table 43.2). Such patients require specialist assessment and collaboration with the local laboratory to rule out confounding disease and pituitary failure.

Table 43.2 Drug effects on thyroid function

  Clinical/biochemical effects
Decrease TSH secretion
Dopamine Hypothyroidism (rarely clinically important)
Glucocorticoids
Octreotide
Alter thyroid hormone secretion
Iodide (amiodarone, contrast agents) Both hyper- and hypothyroidism
Lithium Hypothyroidism
Decrease T4 absorption
Colestyramine/colestipol Increased thyroxine dose requirement
Aluminium hydroxide
Ferrous sulphate
Calcium carbonate
Multivitamins
Sevelamer
Protein pump inhibitors
Sucralfate
Alter T4 and T3 metabolism
Increased hepatic metabolism
Phenobarbital Low T4 and T3 levels
Phenytoin Normal or increased TSH
Rifampicin
Carbamazepine
Reduce conversion of T4 to T3
B-blockers Lower T3 levels
Propylthiouracil Normal or increased TSH
Amiodarone
Glucocorticoids
Reduce T4 and T3 binding
Furosemide Increased measured free T4 in some assays
Salicylates and NSAIDs
Heparin
Increase thyroglobulin levels
Oestrogen and tamoxifen Increased total T4
Opiates and methadone
Others
Cytokines – interferon and interleukin 2 Thyroiditis. Can produce hypothyroidism and thyrotoxicosis

Treatment

The aims of treatment with thyroxine are to ensure that patients receive a dose that will restore well-being and that usually returns the TSH level to the lower end of the normal range (Vanderpump et al., 1996). All patients with symptomatic hypothyroidism require replacement therapy. T4 is usually the treatment of choice except in myxoedema coma where T3 may be used in the first instance. Before commencing T4 replacement, the diagnosis of glucocorticoid deficiency must be excluded to prevent precipitation of a hypoadrenal crisis. If in doubt, hydrocortisone replacement should be given concomitantly until cortisol deficiency is excluded.

The initial dose of T4 will depend on the patient’s age, severity and duration of disease and the coexistence of cardiac disease. In young, healthy patients with disease of short duration, T4 may be commenced in a dose of 50–100 μcg daily. As the drug has a long half-life, it should be given once daily. The most convenient time is usually in the morning. After 6 weeks on the same dose (not a shorter interval as TSH takes this time to stabilise after a dose change), thyroid function tests should be checked. The TSH concentration is the best indicator of the thyroid state, and this should be used for further dosage adjustment. A raised TSH concentration indicates inadequate treatment, poor adherence or both. The majority of patients will be controlled with doses of 100–200 μcg daily, with few patients requiring more than 200 μcg. In adults, the median dose required to suppress TSH to normal is 125 μcg daily. In the majority of patients, once the appropriate dose has been established, it remains constant. During pregnancy, an increase in the dose of thyroxine by 25–50% is needed to maintain normal TSH levels.

Exacerbation of myocardial ischaemia, infarction and sudden death are all well-recognised complications of T4 replacement therapy. Patients with coronary heart disease may be unable to tolerate full replacement doses because of palpitations, angina or heart failure. Elderly patients may have undiagnosed ischemic heart disease. In these two groups of patients, treatment should therefore be started with 25 μcg daily and increased slowly by 25 μcg every 4–6 weeks. During this time, the patient’s clinical progress should be carefully monitored. In some patients, T4 may be better tolerated if a β-blocker such as propranolol is given concomitantly. Some authorities recommend starting with 5 μcg of T3, the rationale being that if adverse effects occur, these can be alleviated more rapidly with a dose reduction due to the shorter half-life of T3.

It is important to avoid both under- and overtreatment. Hypothyroidism is very rarely life threatening, but adverse effects may result from prolonged overtreatment (which is indicated by a TSH level suppressed below the normal range). Though T4 exerts an effect on many organs and tissues, it is the effect on bone and the heart that give the greatest cause for concern. There is evidence that bone density is reduced in patients taking excessive T4 replacement therapy (Faber and Galloe, 1994; Uzzan et al., 1996), and that atrial fibrillation is more common if TSH is suppressed (Sawin et al., 1994). In order to minimise the risk of development of these complications, the dose of T4 should be carefully tailored to the needs of each individual patient. Some patients will have undetectable serum TSH levels while taking thyroxine and may complain of recurrent fatigue if the dose is reduced to permit the TSH to rise. In these patients, it may be permissible to leave the dose unchanged if levels of free T4 and T3 are normal, after a discussion of the relative risks and benefits with the patient (Vanderpump et al., 1996).

Patient care

Hypothyroidism requires lifelong treatment with T4. Patients on long-term drug therapy are recognised to have a low adherence with their medication regimen. Treatment with T4 is often terminated because patients feel well and think that treatment is no longer required. Patients should understand the effects of drug holidays on their health and thyroid function tests and should know that a normal TSH indicates adequate dosage. Written advice should be provided and monitoring of dosage should continue annually. There are a series of excellent patient information leaflets available on the British Thyroid Association website at www.british-thyroid-association.org

Despite adequate counselling, some patients persistently forget to take their tablets reliably, leading to variable thyroid state and wildly fluctuating test results. Other patients lack capacity to self-medicate reliably. There is evidence to show that weekly dosing with T4 is a safe and acceptable way to manage this type of patient, in whom family members or community staff can supervise treatment (Grebe et al., 1997; Rangan et al., 2007). There are no guidelines yet published, but in practice, patients are normally started on 500–700 μcg T4 weekly. Dose changes are made in exactly the same way by assessing TSH levels after 6 weeks of stable dosing.

Rarely, patients are seen in whom TSH levels fluctuate or remain elevated despite high doses of thyroxine and in whom adherence seems to be very good. There are a number of possible causes for this, including malabsorption of thyroxine which can be due to coeliac or inflammatory bowel disease or a number of commonly prescribed drugs (Table 43.2). Such patients will need a careful sequential assessment by an endocrine service (Morris, 2009).

Hyperthyroidism/thyrotoxicosis

Hyperthyroidism is defined as the production by the thyroid gland of excessive amounts of thyroid hormones. Thyrotoxicosis refers to the clinical syndrome associated with prolonged exposure to elevated levels of thyroid hormone. This distinction is important when evaluating thyroid function tests (Table 43.3).

Aetiology

Hyperthyroidism is a disorder of various aetiologies. In clinical terms, thyrotoxicosis is the result of persistently elevated levels of thyroid hormones.

Thyroiditis

Buy Membership for Basic Science Category to continue reading. Learn more here